



IMAGION BIOSYSTEMS LIMITED

(ASX: **IBX**)

20 September 2018

Pro-Rata Non-Renounceable Rights Issue

- Funds to finance the Company's First-in-Human study for metastatic breast cancer and for general working capital
- 1-for-2 pro-rata non-renounceable rights issue at an issue price of \$0.04 per share to raise up to \$4.3 million
- Shortfall facility to enable applications for additional shares

Overview of the Offer

Imagion Biosystems Limited (ASX: **IBX**) (**Imagion** or the **Company**) is pleased to announce a pro-rata non-renounceable rights issue (**Offer**) to shareholders, on the basis of 1 new share for every 2 Imagion shares held as at 7.00pm (Melbourne time) Friday 28 September 2018 (**Record Date**).

Pursuant to the Offer, the Company will issue up to 107,147,608 fully paid ordinary shares in the capital of the Company (**New Shares**) (subject to fractional rounding) at an issue price of \$0.04 each, to raise up to \$4.3 million (before costs). The entitlement to subscribe for New Shares under the Offer will be non-renounceable.

Following from the Company's recent announcement regarding successful optimization of its nanoparticle formulation, the Company is raising funds to support the first-in-human study, which is expected to be conducted at the MD Anderson Cancer Center in early 2019 after small scale production transfer and safety testing. The funds raised will ensure the Company has adequate resources to undertake and complete this early feasibility study which has previously been disclosed as an important milestone in the product development and regulatory path.

Eligibility to participate

The Offer will be made to:

- Shareholders who are registered as holders of existing shares as at the Record Date; and
- Shareholders who have a registered address on the Company's share register that is in Australia, New Zealand or United States where the Offer falls within a security offer exception, and such exception is applicable to those shareholders in that jurisdiction at that time (**Eligible Shareholders**)

The Company has determined that it would be unreasonable to extend the Offer to shareholders who are not Eligible Shareholders (**Ineligible Shareholders**) having regard to:

- the small number of shareholders with addresses in other countries;
- the number and value of the shares they hold; and
- the cost to the Company of complying with applicable legal and regulatory requirements in such other countries.



Dispersion strategies

There will be a shortfall facility under the Offer, which will enable Eligible Shareholders to subscribe for shares in addition to their entitlement.

In the event that following the close of the Offer a shortfall remains, the Directors reserve the right to place such shortfall shares at their discretion with persons interested in subscribing for shares in the Company within 3 months of the close of the Offer.

New Shares issued under the Offer

The number of issued shares at the date of this announcement and the total number of issued shares following the Offer are as follows:

Event	Number of Shares
Shares currently on issue	214,295,216
New Shares issued pursuant to the Offer	107,147,608
Total shares on issue after completion of the Offer	321,442,824

The New Shares issued under the Offer will be fully paid and will rank equally with the Company's existing Shares on issue. The Company will make an application to the ASX for official quotation of the New Shares.

Purpose of the Offer

The purpose of the Offer is to raise funds. The Directors intend to apply the funds to ensure the Company has adequate resources to undertake and complete this early feasibility study which has previously been disclosed as an important milestone in the product development and regulatory path. This includes general R&D support and costs to support first-in-human studies and general working capital.

Offer timetable

EVENT	DATE (2018)
Announcement of the Offer	Thursday 20 September
Lodgement of the following documents with ASX: <ul style="list-style-type: none"> ▪ an Appendix 3B; ▪ the Offer Document; and ▪ a cleansing notice under section 708AA(2)(f) of the Corporations Act ▪ Letter to option holders 	Monday, 24 September
Notice sent to option holders advising that they cannot participate in the Offer without first exercising their options	Monday, 24 September
Notice sent to Shareholders containing ASX Appendix 3B details and indicative timetable	Tuesday, 25 September



"Ex" date where the Company's existing shares will commence trading without the entitlement to participate in the Offer	Thursday 27 September
Record date to determine Entitlements under the Offer	7.00pm (Melbourne time) Friday 28 September
Opening Date for the Offer	Wednesday 3 October
Mailing of Offer Document and Entitlement and Acceptance Form to Eligible Shareholders	Wednesday 3 October
Last day to extend Offer Closing Date	Friday 12 October
Closing Date for the Offer	5.00pm (Melbourne time) Wednesday 17 October
Shares quoted on a deferred settlement basis	Thursday 18 October
ASX notified of under subscriptions	Friday 19 October
New Shares for which valid applications have been received and accepted by the Company will be issued	Wednesday 24 October
Deferred settlement trading ends	Wednesday 24 October
Normal trading of New Shares on ASX expected to commence	Thursday 25 October
Deadline for placement of remaining shortfall	Friday 11 January 2019

This timetable is indicative only and subject to change. Subject to the *Corporations Act 2001* (Cth) and the ASX Listing Rules, the Board reserves the right to vary these dates, including the closing date of the Offer, without prior notice.

The Company also reserves the right not to proceed with the whole or part of the Offer at any time prior to the issue date. In that event, application monies will be refunded in full without interest.

Full details of the terms and conditions of the Offer will be contained in the Offer document to be lodged with ASX and dispatched to Eligible Shareholders in accordance with the timetable set out above.

-ENDS

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:

Matthew Wygant

matthew@biotechwriting.com

+1-408-905-7630

Australian Media & Investor Relations:

Matt Wright, NWR Communications

matt@nwrcommunications.com.au

+61-451-896-420



About Imagion Biosystems

Imagion Biosystems is at the crossroads of biotechnology and nanotechnology. Its novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher specificity than is currently possible. With MagSense™ technology, the company has the potential to optimize patient care and reduce mortality rates across various cancer indications. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.